Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis

• المؤلفون الرئيسيون: Weichen Zhang (مؤلف), Meichen Yu (مؤلف), Guohua Cheng (مؤلف)
• التنسيق: كتاب
• منشور في: Frontiers Media S.A., 2024-04-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Background and aim:Dapagliflozin inhibits the sodium-glucose cotransporter protein 2 (SGLT-2), while sotagliflozin, belonging to a new class of dual-acting SGLT-1/SGLT-2 inhibitors, has garnered considerable attention due to its efficacy and safety. Both Dapagliflozin and sotagliflozin play a signif...